Key result
Glial Growth Factor 2 protected HL-1 cardiomyocytes from doxorubicin-induced toxicity, increasing cell viability by 50% through PI3K-dependent regulation of the BAD/Bcl-2 apoptotic pathway.
GGF2 protects cardiomyocytes from doxorubicin-induced cardiotoxicity by activating the PI3K/Bcl-2 pathway.
Answers are grounded in this paper and cite their sources.
Hypothesis-generating for GGF2 in doxorubicin cardiotoxicity; leaves open clinical translation pending in vivo and human studies.
Neuregulin/erbB signalling is cardioprotective as seen in models of cardiotoxicity associated with the use of chemotherapeutics. Our studies reveal a function of Bcl-2 to protect cardiomyocytes concomitant with GGF2-induced increases in levels of phospho-BAD (pBAD) along with activation of PI3 kinase (PI3K) and MAP kinase (MAPK). We show that phosphorylation of BAD is dependent upon GGF2 mediated activation of PI3K. In addition, examination of mitochondrial gene expression shows several members of the Bcl-2 family are down-regulated by doxorubicin, while GGF2 is able to reverse this effect. While many in vitro model systems of doxorubicin cardiotoxicity have observed PI3K-dependent cytoprotective effects of neuregulin's, the present results demonstrate that GGF2 mediates cytoprotective actions in HL-1 cardiomyocytes through regulation of mitochondrial mediated apoptosis via the PI3K/Bcl-2 pathway.
No takes yet. Share an insight, caveat, or question.
Srinivas et al. (2017) studied Doxorubicin-induced cardiotoxicity. Glial Growth Factor 2 (GGF2) vs. Doxorubicin alone was evaluated on Cell viability (MTT assay) (p=<0.0001). Glial Growth Factor 2 protected HL-1 cardiomyocytes from doxorubicin-induced toxicity, increasing cell viability by 50% through PI3K-dependent regulation of the BAD/Bcl-2 apoptotic pathway.
Synapse has enriched 10 related papers. Consider them for comparative context: